NATCO PHARMA LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,028 INR | +0.66% |
|
+2.85% | +26.69% |
| Apr. 09 | Natco Pharma Gets US FDA Warning Letter after Inspection of Kothur, India Unit | MT |
| Mar. 27 | NATCO Pharma Limited Announces Board Appointments | CI |
Valuation
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 104,796 | 92,044 | 150,529 | 138,013 | 102,795 | 184,107 | - | - |
| Enterprise Value (EV) 1 | 104,796 | 94,543 | 144,657 | 134,169 | 95,949 | 168,441 | 152,534 | 133,186 |
| P/E ratio | 16.4 x | 20 x | 34.2 x | 81.1 x | 14.4 x | 14 x | 12.2 x | 10.6 x |
| Yield | 1.09% | 1.34% | 0.64% | 0.6% | 0.98% | 0.98% | 1.1% | 1.13% |
| Capitalization / Revenue | 5 x | 4.81 x | 7.34 x | 7.1 x | 3.8 x | 4.7 x | 4.08 x | 3.71 x |
| EV / Revenue | 5 x | 4.94 x | 7.05 x | 6.9 x | 3.54 x | 4.3 x | 3.38 x | 2.68 x |
| EV / EBITDA | 13.2 x | 16.2 x | 23.9 x | 50.9 x | 10.3 x | 9.97 x | 7.47 x | 5.81 x |
| EV / FCF | 49.4 x | 154 x | 327 x | -72.1 x | 13.7 x | 24.2 x | 13.6 x | 9.88 x |
| FCF Yield | 2.02% | 0.65% | 0.31% | -1.39% | 7.32% | 4.13% | 7.33% | 10.1% |
| Price to Book | 3 x | 2.44 x | 3.66 x | 3.24 x | 2.11 x | 3.1 x | 2.62 x | 2.17 x |
| Nbr of stocks (in thousands) | 182,746 | 182,068 | 182,338 | 182,520 | 182,470 | 179,110 | - | - |
| Reference price 2 | 573.4 | 505.6 | 825.6 | 756.2 | 563.4 | 1,028 | 1,028 | 1,028 |
| Announcement Date | 5/27/19 | 6/17/20 | 6/17/21 | 5/30/22 | 5/29/23 | - | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 20,945 | 19,150 | 20,521 | 19,448 | 27,071 | 39,185 | 45,132 | 49,636 |
| EBITDA 1 | 7,948 | 5,826 | 6,062 | 2,635 | 9,356 | 16,899 | 20,407 | 22,912 |
| EBIT 1 | 7,138 | 4,828 | 4,893 | 1,209 | 7,718 | 15,221 | 18,331 | 21,163 |
| Operating Margin | 34.08% | 25.21% | 23.84% | 6.22% | 28.51% | 38.84% | 40.62% | 42.64% |
| Earnings before Tax (EBT) 1 | 8,247 | 5,687 | 5,796 | 2,022 | 8,619 | 16,001 | 18,678 | 21,651 |
| Net income 1 | 6,444 | 4,608 | 4,409 | 1,700 | 7,153 | 13,212 | 15,273 | 17,622 |
| Net margin | 30.77% | 24.06% | 21.49% | 8.74% | 26.42% | 33.72% | 33.84% | 35.5% |
| EPS 2 | 34.87 | 25.26 | 24.16 | 9.320 | 39.18 | 73.23 | 84.34 | 97.31 |
| Free Cash Flow 1 | 2,122 | 615 | 442 | -1,862 | 7,028 | 6,961 | 11,183 | 13,478 |
| FCF margin | 10.13% | 3.21% | 2.15% | -9.57% | 25.96% | 17.76% | 24.78% | 27.15% |
| FCF Conversion (EBITDA) | 26.7% | 10.56% | 7.29% | - | 75.12% | 41.19% | 54.8% | 58.82% |
| FCF Conversion (Net income) | 32.93% | 13.35% | 10.02% | - | 98.25% | 52.69% | 73.22% | 76.48% |
| Dividend per Share 2 | 6.250 | 6.750 | 5.250 | 4.500 | 5.500 | 10.02 | 11.30 | 11.60 |
| Announcement Date | 5/27/19 | 6/17/20 | 6/17/21 | 5/30/22 | 5/29/23 | - | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 3,552 | 3,313 | 4,103 | 3,772 | 5,605 | 5,968 | 8,846 | 4,321 | 4,925 | 8,979 | 11,405 | 10,790 | 5,742 | 9,922 |
| EBITDA 1 | 825 | 762 | 1,098 | 705 | 1,018 | -186 | 3,953 | 953 | 1,059 | 3,391 | 5,280 | 4,930 | 1,284 | 4,376 |
| EBIT | - | - | - | - | - | - | - | - | - | - | - | - | 692 | 3,504 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | 12.05% | 35.32% |
| Earnings before Tax (EBT) 1 | - | - | 910 | 698 | 910 | -496 | 3,858 | - | 814 | 3,244 | 5,000 | 4,672 | - | 4,732 |
| Net income 1 | 627 | 530 | 750 | 651 | 804 | -505 | 3,204 | 568 | 623 | 2,758 | 4,203 | 5,355 | 833.2 | 3,241 |
| Net margin | 17.65% | 16% | 18.28% | 17.26% | 14.34% | -8.46% | 36.22% | 13.15% | 12.65% | 30.72% | 36.85% | 49.63% | 14.51% | 32.67% |
| EPS 2 | 3.430 | - | 4.110 | 3.570 | 4.400 | -2.770 | 17.55 | 3.110 | 3.410 | 15.11 | 23.26 | 21.42 | 3.680 | 15.00 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/11/21 | 6/17/21 | 8/12/21 | 11/11/21 | 2/14/22 | 5/30/22 | 8/9/22 | 11/10/22 | 2/9/23 | 5/29/23 | 8/9/23 | - | - | - |
1INR in Million2INR
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | 2,499 | - | - | - | - | - | - |
| Net Cash position 1 | - | - | 5,872 | 3,844 | 6,846 | 15,666 | 31,573 | 50,921 |
| Leverage (Debt/EBITDA) | - | 0.4289 x | - | - | - | - | - | - |
| Free Cash Flow 1 | 2,122 | 615 | 442 | -1,862 | 7,028 | 6,961 | 11,183 | 13,478 |
| ROE (net income / shareholders' equity) | 19.6% | 12.7% | 11.2% | 4.05% | 15.7% | 24.1% | 23.2% | 20.3% |
| ROA (Net income/ Total Assets) | - | 10.4% | 9.4% | 3.43% | - | - | - | - |
| Assets 1 | - | 44,454 | 46,898 | 49,505 | - | - | - | - |
| Book Value Per Share 2 | 191.0 | 207.0 | 226.0 | 234.0 | 267.0 | 332.0 | 392.0 | 474.0 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 4,566 | 3,558 | 2,546 | 2,327 | 1,463 | 2,692 | 2,748 | 2,697 |
| Capex / Sales | 21.8% | 18.58% | 12.41% | 11.97% | 5.4% | 6.87% | 6.09% | 5.43% |
| Announcement Date | 5/27/19 | 6/17/20 | 6/17/21 | 5/30/22 | 5/29/23 | - | - | - |
1INR in Million2INR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
1,028
INR
Average target price
975.4
INR
Spread / Average Target
-5.11%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +26.69% | 2.21B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- NATCOPHARM Stock
- Financials NATCO Pharma Limited
